Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Instagram Outage Disrupts Thousands of U.S. Users 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
BioPorto Diagnostics and QIAGEN have successfully validated the use of BioPorto’s gRAD lateral flow platform on QIAGENS’s ESEQuant LR3 Lateral Flow System.
By combining gRAD with the ESEQuant LRS system, this platform, provides a powerful and versatile toolbox for rapid development of lateral flow-based assays. This toolbox is well suited in the constantly shifting lateral flow market space, where the demand for new applications in human diagnostics, veterinary diagnostics, food industry and environmental/agriculture testing is rapidly increasing.
Jan Kuhlmann Andersen, COO of BioPorto, commented: “With the gRAD platform BioPorto Diagnostics has the ability to offer assay developers across several industries contract development of their assay development. Through the combination of gRAD and the ESEQuant LRS system, BioPorto now has a complete assay development process in place to test across above mentioned business segments.”
Read more about the gRAD lateral flow technology and the ESEQuant LR3 Lateral Flow technology.
www.bioporto.com/Products/Product-by-category/Lateral-flow.aspx
http://www.lateralflowreader.com/new-powerful-option-esequant-lr3-grad/
For further information, please contact:
Peter Mørch Eriksen, CEO
Gry Husby Larsen, General Counsel
Telephone +45 4529 0000, e-mail [email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/3275dac8-8136-4c84-a74d-b229acccc5eb
